Cathie Wood’s ARK sells Circle Internet stock, buys Figma shares By Investing.com

ARK disclosed large rebalancing on Mar 20, 2026: the biggest trade was a sale of 45,998 CRCL shares for $5,902,923 and a $8,171,367 purchase of 337,381 FIG shares. Other notable moves included selling 19,206 TER shares for $5,807,894, selling 103,379 BLSH for $4,093,808, buying 192,658 TXG shares for $3,541,054, selling 182,353 BFLY for $723,941, selling 9,621 GH for $857,038, and buying 22,773 ARCT for $153,034. These transactions signal sector rotation and position reshaping across technology and healthcare, likely to influence the cited small- to mid-cap names more than broad markets.

Analysis

ARK’s activity reads as a flow-driven rotation: accumulation in design/software and genomic tools (FIG, TXG) is likely to compress liquidity in small-to-mid cap tech and amplify momentum signals for retail and quant programs over the next 2–8 weeks. That dynamic creates an asymmetric short-term impact where 2–5% ETF rebalances can move bid/ask by multiple ticks in names with daily ADV < $50m, raising temporary slippage for buyers and creating tactical short opportunities for sellers willing to carry execution risk.

Second-order beneficiaries include server and systems vendors that supply compute to design and genomics workflows (SMCI-type exposure) — incremental FIG/TXG adoption translates into outsized near-term capex elasticity versus legacy enterprise software because compute and storage scale non-linearly with active user growth. Conversely, repeated trimming of niche healthcare and imaging names increases funding pressure: smaller biotechs face higher cost of capital if their primary holders de-risk, accelerating M&A or dilution timelines within 3–12 months.

The principal risks that would reverse these moves are twofold: near-term liquidity shocks (large ETF outflows or a macro risk-off) that force stops across momentum holders within days, and multi-quarter fundamental setbacks (missed adoption metrics for FIG, weaker sequencing or instrument demand for TXG) that can unwind positioning over months. Execution matters: use size that tolerates 3–7% intraday repricing for thin names and prioritize options to cap downside where implied vols are reasonable.

Key Decisions for Investors

• Long FIG (FIG): Initiate a tactical 0.5–1.0% NAV position, target +30–40% in 6–12 months if adoption KPIs and revenue cadence remain intact; stop-loss at -18% or hedge with a 6-month 10% OTM put to limit downside to ~2% NAV.
• Long 10x Genomics (TXG): Buy a 3–6 month call spread (buy 1x ATM, sell 1x 30% OTM) representing ~0.75% NAV to capture further accumulation-driven momentum; target 2.5x premium if sequencing kit upgrades or instrument shipments beat expectations, risk limited to premium paid (~1% NAV).
• Pairs trade — Short Butterfly Network (BFLY) / Long Super Micro (SMCI): Size net-neutral (e.g., 0.6% NAV short BFLY vs 0.6% NAV long SMCI). Rationale: rotate out of niche imaging into compute infra; target 25% relative outperformance in 3–9 months, tight stop on the short at +25% and on the long at -18%.
• Event hedge — Short CRCL via puts or short-dated futures/options: Deploy a small hedge (0.25–0.5% NAV) using 3-month puts ~15–20% OTM to protect against flow-induced downside from continued ETF selling; expected payoff if CRCL gaps down >15% from current levels, cost capped to the premium.